XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Business Overview and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of estimated useful lives of property, plant, and equipment The estimated useful lives of property, plant, and equipment are as follows:
Building and improvements
10–50 years
Laboratory and other equipment
3–10 years
Furniture and fixtures
5 years
Property, plant, and equipment consists of the following:
As of December 31,
(In millions)20222021
Land$264.5 $248.0 
Building and improvements2,270.0 2,088.5 
Leasehold improvements114.3 113.9 
Construction in progress980.5 767.7 
Laboratory equipment1,315.3 1,225.5 
Computer equipment and software337.4 291.5 
Furniture, office equipment, and other
150.2 145.2 
5,432.2 4,880.3 
Less, accumulated depreciation and amortization
(1,669.2)(1,398.1)
$3,763.0 $3,482.2 
Summary of presentation in statement of operations of payments to and from collaborators
In arrangements where the Company does not deem its collaborator to be its customer, payments to and from its collaborator are presented in the Company's statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below.
Nature/Type of PaymentStatement of Operations Presentation
Regeneron's share of profits or losses in connection with commercialization of products
Collaboration revenue
Reimbursement for manufacturing of commercial supplies
Collaboration revenue
Royalties and/or sales-based milestones earnedCollaboration revenue
Reimbursement of Regeneron's research and development expenses
Reduction to Research and development expenses
Regeneron's obligation for its share of collaborator's research and development expenses
Research and development expense
Up-front/opt-in and development milestone payments to collaboratorsAcquired in-process research and development expense
Reimbursement of Regeneron's commercialization-related expenses
Reduction to Selling, general, and administrative expense
Regeneron's obligation for its share of collaborator's commercialization-related expenses
Selling, general, and administrative expense
Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal
Cost of goods sold
Up-front and development milestones earned (when there is a combined unit of account which includes a license and providing research and development services)Other operating income